D uring the past decade, there has been a striking increase in the prevalence of Clostridium difficile infection and in associated mortality in the United States, Canada, and Europe. [1] [2] [3] [4] [5] The widespread use of broad-spectrum antibiotics places patients at risk for C. difficile diarrhea or colitis and has changed the epidemiology of C. difficile infection. This has been characterized by the emergence of a hypervirulent strain of C. difficile (BI/NAP1/027) and an increasing risk of treatment failure and recurrent infection. 1, [6] [7] [8] [9] [10] [11] [12] [13] [14] We developed one fully human monoclonal antibody targeted against C. difficile toxin A (CDA1) and a second against toxin B (CDB1). We have found significant efficacy for the combined antibodies in an established hamster model of C. difficile infection, as well as safety in a phase 1 study in healthy volunteers. 15 We now report a phase 2 randomized, double-blind, placebo-controlled trial of the efficacy of CDA1 plus CDB1 in preventing the recurrence of C. difficile infection. We also examined the safety of this therapy and its effects on the duration and severity of the initial episode of infection and on duration of hospitalization.
Me thods

Patients
From July 2006 through April 2008, patients were enrolled at 30 study sites in the United States and Canada. Eligible patients were at least 18 years of age and had diarrhea associated with a positive stool test for a C. difficile toxin in the 14 days before enrollment. The enzyme immunoassay method for stool toxin detection that was in use at each study site was also used for this study. Patients were required to be receiving either metronidazole or oral vancomycin for the treatment of the C. difficile infection, with the choice of antibiotic made by the treating physician. Diarrhea was defined as three or more unformed stools per day for at least 2 consecutive days or more than six unformed stools in 1 day. 16 Patients could have started receiving antibiotic treatment at any time before enrollment but must have had diarrhea on the day of enrollment. The protocol was approved by the institutional review board or ethics committee at each study site and by the governmental regulatory authorities in the United States and Canada. All patients provided written informed consent.
Study Design and Oversight
This study was designed and supervised by the sponsors, MassBiologics and Medarex. Data were collected by principal investigators at each study site, and statistical analyses were performed by an independent statistician who was supervised by the sponsors. An independent data and safety monitoring board was responsible for monitoring the safety of the patients during the trial and the performance of the primary end-point analysis at the time of breaking the blind. Two authors who are employed by the sponsors wrote the first draft of the manuscript. All the authors vouch for the accuracy and completeness of the data reported.
Randomization and Follow-Up
Enrolled patients were randomly assigned to receive an intravenous infusion of either CDA1-CDB1 or 0.9% sodium chloride as placebo in a 1:1 ratio. Stool specimens were collected at enrollment and were processed for the identification of C. difficile by culture on selective prereduced taurocholatecefoxitin-cycloserine-fructose agar (TCCFA) and typed by restriction endonuclease analysis in a blinded fashion, as described previously. 17,18 Current epidemic C. difficile isolates have been identified as group BI on restriction endonuclease analysis, NAP1 on pulsed-field gel electrophoresis, and 027 on ribotyping (BI/NAP1/027) with the use of polymerase-chain-reaction (PCR) assay. 18 On the first day of the study, during a 2-hour period, patients received a single intravenous infusion of 10 mg each of CDA1 and CDB1 per kilogram of body weight in a total volume of 200 ml (with 0.9% sodium chloride as the diluent) or placebo. Stool counts were recorded daily for the 84-day study period with the use of a memory aid to track the number and type of stools. This information was reviewed by study staff, either in person or through telephone contact. Patients were contacted on a daily basis through day 14 after infusion, weekly through day 56, and then monthly until day 84, with in-person visits on days 3±1, 10±2, 28±3, 56±7, and 84±10, which included blood-sample collection. The first 20 patients who were enrolled had an additional visit on day 168±14 to obtain a blood sample for immunogenicity analysis.
of diarrhea associated with a new positive stool toxin test after the resolution of the initial CDI diarrheal episode and after discontinuation of metronidazole or vancomycin. Only the first episode of CDI recurrence was evaluated in the efficacy analyses. Secondary end points included the number of days to the resolution of the initial episode, severity of the initial episode, and failure of antibiotic treatment (as defined as a change in antibiotics or persistence of diarrhea at day 14 of antibiotic administration). Levels of serum antibodies against toxins A and B were measured in all patients by enzyme-linked immunosorbent assay (ELISA) with the use of fragment 4 of the toxins as the target 19 (for details, see the Laboratory Assays section in the Supplementary Appendix, available with the full text of this article at NEJM.org).
Safety Assessments
Evaluation for safety included the measurement of vital signs, the taking of an interim medical history, and physical assessment if clinically indicated for adverse events at all study visits. Laboratory testing of hematologic and serum chemical values and urinalysis were performed at study visits through day 28±3. Solicited reports of adverse events were collected by study personnel during the infusion and the 2-hour period after infusion. Adverse events were graded according to the Adult Toxicity Table (May 2001) , as adapted by the National Institute of Allergy and Infectious Diseases. The detection of human antihuman antibody in response to the monoclonal antibodies was determined with the use of a bridging ELISA 19 (see the Laboratory Assays section in the Supplementary Appendix).
Statistical Analysis
The target study enrollment of 200 patients was based on an ability to observe a reduction in recurrence rates from 20% in the placebo group to 6% in the antibody group with a power of 80%. All statistical methods were specified before study enrollment, and the final statistical-analysis plan was approved before blinding was broken. All analy ses were performed with JMP software, version 7.0 (SAS Institute), and StatXact (Cytel Software).
We analyzed primary and secondary efficacy end points (as prespecified in the statistical-analysis plan) on the intention-to-treat principle and included all patients who underwent randomization (see the Methods section in the Supplementary Appendix). Each subgroup (except for the subgroups defined according to hospitalization status) was prespecified in the statistical-analysis plan at enrollment. Analysis of additional hospitalizations during the study period was performed post hoc. Nominal variables were compared between the study groups with the use of a twosided Fisher's exact test with 95% confidence intervals. Continuous variables were compared with the use of a two-sided t-test. Kaplan-Meier plots were used to analyze time-to-event variables, which were compared by means of log-rank tests. A P value of less than 0.05 was considered to indicate statistical significance.
R esult s
Patients
Of 7396 patients who were assessed for eligibility, 484 were screened, and 200 patients from 30 participating centers were enrolled. The mean age of the patients was 64 years (range, 20 to 101). Of these patients, 101 were randomly assigned to receive CDA1-CDB1 antibody treatment and 99 to receive placebo ( Fig. 1 in the Supplementary Appendix). Baseline characteristics were similar between the two study groups, except for a higher mean number of unformed stools at screening and at the time of infusion in the antibody group than in the placebo group (Table 1) . Exposure to antibiotics other than metronidazole or vancomycin from the day of study infusion through day 84 occurred in 40 patients (40%) in the antibody group and 48 patients (48%) in the placebo group (P = 0.26).
Efficacy
The primary efficacy end point was laboratorydocumented recurrence of C. difficile infection, which was observed in 32 patients: 7% in the antibody group and 25% in the placebo group (95% confidence interval [CI], 7 to 29; P<0.001). Significant reductions were also observed for less rigorous and more inclusive definitions of recurrence in both the intention-to-treat and per-protocol populations. In a comparison of recurrent diarrhea with or without laboratory confirmation of C. difficile infection and with or without antibiotic treatment for C. difficile infection, 28% of patients in the antibody group had recurrent diarrhea, as com-pared with 50% of those in the placebo group (P = 0.002) (see the Methods section and Table 1 in the Supplementary Appendix).
Kaplan-Meier analysis showed that the time to recurrence of C. difficile infection differed significantly between the two study groups (P<0.001) (Fig. 1) . The relative risk of recurrence on the basis of total days of follow-up for each study group was significantly lower in the antibody group (relative risk, 0.23; 95% CI, 0.08 to 0.54; P = 0.01).
The effect of CDA1-CDB1 on the severity of diarrhea during the initial episode was also assessed as a secondary end point. Severe diarrhea was defined as at least five unformed stools per day for at least 2 consecutive days, starting with the stool counts recorded on day 1 through cessation of diarrhea and discontinuation of antibiotic treatment for the initial episode. There were no significant differences between the antibody group and the placebo group in the severity of diarrhea during the initial episode of C. difficile infection, the median or mean number of days to the resolution of the initial episode, or the proportion of patients in whom treatment failed, according to the protocol definition of failure of antibiotic treatment. 
Subgroup Analyses
For subgroups of patients that were prespecified in the statistical-analysis plan, CDA1-CDB1 treatment was effective with either concomitant vancomycin or metronidazole treatment, in patients with epidemic strain BI/NAP1/027 or nonepidemic strains of C. difficile, and in patients with their first episode of infection or those with multiple previous episodes ( Table 2 ). All recurrent episodes in the antibody group were in patients who had been hospitalized during their initial episode. The subgroup analysis for hospitalization status was performed post hoc. Inpatients were significantly older and had a significantly higher score on Horn's index (indicating greater severity of underlying illness) than did outpatients, and there was a trend toward more severe infection at enrollment among such patients ( 
Hospital Admission after First Episode
The mean length of hospitalization for the initial episode of C. difficile infection did not differ significantly between the antibody group and the placebo group (9.5 and 9.4 days, respectively), nor did the total number of hospital days during the 84-day study period (data not shown). However, in a post hoc analysis, the proportion of patients who were admitted to the hospital after the study infusion differed significantly: 9% of the patients in the antibody group as compared with 20% of those in the placebo group (P = 0.03). An exploratory analysis of the admission diagnoses for these hospitalizations suggests that coexisting illnesses that were related to C. difficile infection (e.g., diarrhea, dehydration, and hypotension) were responsible for many of these hospitalizations, accounting for 5 of the 9 admissions in the antibody group and 16 of the 20 admissions in the placebo group, even if they did not meet the criteria for recurrent infection at that admission.
Pharmacokinetics
Serum levels of antitoxin A and antitoxin B were measured in all patients before and after the study infusion (Fig. 2) . For patients in the antibody group, the mean (±SD) half-life of the terminal portion of the disposition phase was 26±8.4 days for antitoxin A and 22±13 days for antitoxin B. For patients in the placebo group whose serum antitoxin antibodies represented their endogenous response over time, the majority of patients who had a recurrence of infection had low or no detectable levels of antibodies against either toxin.
Adverse Events
There were no significant differences in vital signs between the two study groups during and up to 2 hours after infusion. Adverse events were reported in 14 patients (9 in the antibody group and 5 in the placebo group) during infusion and in 11 patients (6 in the antibody group and 5 in the placebo group) during the 2-hour period after infusion. All adverse events were mild to moderate in nature, with headache reported most frequently in both groups. There were seven deaths in the antibody group and eight in the placebo group during the study period (P = 0.79); no deaths were attributed to a study drug (see the Results section in the Supplementary Appendix). At least one serious adverse event was reported by 18 patients in The cumulative percentages of 32 patients with laboratory-documented recurrent CDI during the 84-day study period are shown for the two study groups: 7% in the antibody group and 25% in the placebo group. Five patients had a second episode of CDI recurrence: two in the antibody group and three in the placebo group. The P value was calculated by means of the log-rank test.
the antibody group and 28 patients in the placebo group (P = 0.09).
The proportions of patients with the most frequent grade 3 or 4 adverse events were similar in the two study groups, except for significantly fewer reports of hypotension in the antibody group (Table 3) . Analysis of adverse events during the overall study period revealed several nonserious adverse events (including anorexia, anxiety, diarrhea, depression, and insomnia) that were significantly less common in the antibody group than in the placebo group (Table 3 in the Supplementary Appendix) .
To examine the immunogenicity of the monoclonal antibodies, human antihuman antibody titers in response to CDA1 and CDB1 were assessed before and after study infusion at multiple time points. Two patients in the antibody group had a positive titer before infusion; one of these patients had no detectable titer after infusion, and the other patient's titer was unchanged after infusion. In 20 patients (8 in the antibody group and 12 in the placebo group) who were followed for 6 months (last assessment, day 168 plus or minus 14) after infusion, human antihuman antibody titers were not detected.
Discussion
In our study, the administration of fully human monoclonal antibodies favorably affected the natural history of C. difficile infection when added to treatment with metronidazole or vancomycin. A single infusion of two monoclonal antibodies against C. difficile toxins A and B (CDA1 and CDB1) resulted in a reduction of the rate of recurrent infection among patients treated with standardof-care antibiotics. Although the primary end point of the study was a reduction in the rate of recurrence, secondary end points evaluated the effect of monoclonal-antibody treatment on the initial episode of infection. The time to the resolution of diarrhea, number of days of hospitalization for the initial episode, and severity of diarrhea during the initial episode were similar in the two study groups. CDA1 and CDB1 are fully human antibodies, each of which targets an exogenous antigen. Immunogenicity was not detected in any patient during the study period.
Larger studies will need to be conducted to confirm the findings of this phase 2 study. Our results are consistent with those of previous studies that correlated serum levels of antitoxin an- tibodies with protection against C. difficile infection. 16, [20] [21] [22] The efficacy of neutralizing antibodies against toxins A and B administered as combined treatment is also consistent with data in animal models. [23] [24] [25] [26] Although recent evidence in a hamster model of disease indicated that toxin B is essential for virulence and toxin A may not be, 27 the treatment of human disease may benefit from the presence of high-affinity antibodies against both toxins. The doses of CDA1 and CDB1 that were chosen for our study were based on protective doses in animal models 15 and observed pharmacokinetics in humans. All cases of recurrence in the antibody group were in patients who were hospitalized at the time of enrollment in the study. At enrollment, the inpatients were significantly older and had a significantly higher index of severity of underlying illness than did outpatients -two factors associated with an increased risk of recurrence. 20 For the seven inpatients who had a recurrence of C. difficile infection despite CDA1-CDB1 treatment, serum levels of antitoxin antibodies did not appear to be lower than those in patients in the antibody group who did not have a recurrence. The reasons for recurrence in these patients despite high levels of neutralizing antitoxin antibodies are not clear but may be related to impairment of local or other systemic host immune mechanisms. Also, serum levels of neutralizing antibodies may not always reflect adequate levels in the intestinal mucosa. Although higher doses of CDA1-CDB1 could potentially further improve the outcome, the large effect size of a 72% reduction in recurrence seen with these doses supports the use of the current doses in future studies. The combined administration of CDA1 and CDB1 human monoclonal antibodies in addition to antibiotics significantly reduced the recurrence of C. difficile infection. Furthermore, the administration of a single intravenous dose of antibody may be advantageous, depending on the patient's ability to take oral medications. This novel treatment deserves further study as a means to reduce the morbidity and health care burden of C. difficile infection in the face of the increased incidence and severity of the disease worldwide.
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